Goodman GP, Engh CA, Goyal N. Revision total hip

arthroplasty exposure considerations: Which way in?

Seminars in Arthroplasty. 2015;26(3):150-155.

Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS,

Schuler M, et al. Clinical activity of afatinib in patients

with advanced non-small-cell lung cancer harbouring

uncommon EGFR mutations: a combined post-hoc analysis

of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet

Oncol. 2015;16(7):830-8.

Dungo RT, Keating GM. Afatinib: first global approval.

Drugs. 2013;73:1503-1515.

Hirsch FR, Varella-Garcia M, Bunn Jr PA, Di Maria MV,

Veve R, Bremnes RM, et al. Epidermal growth factor

receptor in non–small-cell lung carcinomas: correlation

between gene copy number and protein expression

and impact on prognosis. Journal of clinical oncology.

;21(20):3798-3807.

Borgeaud M, Parikh K, Banna GL, Kim F, Olivier T, Le

X, et al. Unveiling the Landscape of uncommon EGFR

Mutations in Non-Small Cell Lung Cancer-A Systematic

Review. Journal of Thoracic Oncology. 2024.

Hsu P-C, Lee S-H, Chiu L-C, Lee C-S, Wu C-E, Kuo

SC-H, et al. Afatinib in untreated stage IIIB/IV lung

adenocarcinoma with major uncommon epidermal growth

factor receptor (EGFR) mutations (G719X/L861Q/S768I):

a multicenter observational study in Taiwan. Targeted

Oncology. 2023;18(2):195-207.

Thanh VH, Hòa NTT. KẾT QUẢ ĐIỀU TRỊ AFATINIB

BƯỚC 1 TRÊN UNG THƯ PHỔI KHÔNG TẾ BÀO

NHỎ, GIAI ĐOẠN TIẾN XA, LOẠI BIỂU MÔ TUYẾN,

CÓ ĐỘT BIẾN HIẾM GẶP CỦA GEN EGFR TẠI BỆNH

VIỆN K.

Pham VL, Le TA, Pham CP, Hoa Nguyen TT, Do AT,

Nguyen TK, et al. Real-world analysis of afatinib as a

first-line treatment for patients with advanced stage nonsmall-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam. Therapeutic Advances in

Medical Oncology. 2024;16:17588359241242972.

Janning M, Süptitz J, Albers-Leischner C, Delpy P, Tufman

A, Velthaus-Rusik J-L, et al. Treatment outcome of atypical

EGFR mutations in the German national network genomic

medicine lung cancer (nNGM). Annals of oncology.

;33(6):602-615.

Shen YC, Tseng GC, Tu CY, Chen WC, Liao WC,

Chen WC, et al. Comparing the effects of afatinib with

gefitinib or Erlotinib in patients with advanced-stage lung

adenocarcinoma harboring non-classical epidermal growth

factor receptor mutations. Lung Cancer. 2017;110:56-62.

Tu C-Y, Chen C-M, Liao W-C, Wu B-R, Chen C-Y, Chen

W-C, et al. Comparison of the effects of the three major

tyrosine kinase inhibitors as first-line therapy for nonsmall-cell lung cancer harboring epidermal growth factor

receptor mutations. Oncotarget. 2018;9(36):24237.

Yang JC-H, Schuler M, Popat S, Miura S, Heeke S, Park

K, et al. Afatinib for the treatment of NSCLC harboring

uncommon EGFR mutations: a database of 693 cases.

Journal of Thoracic Oncology. 2020;15(5):803-815.

Schuler M, Wu Y-L, Hirsh V, O’Byrne K, Yamamoto N,

Mok T, et al. First-line afatinib versus chemotherapy in

patients with non–small cell lung cancer and common

epidermal growth factor receptor gene mutations

and brain metastases. Journal of Thoracic Oncology.

;11(3):380-390.

Kang L, Mai J, Liang W, Zou Q, Huang C, Lin Y, et al.

CNS efficacy of afatinib as first-line treatment in advanced

non-small cell lung cancer patients with EGFR mutations.

Frontiers in Oncology. 2023;13:1094195.

Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T,

Chewaskulyong B, Lee KH, et al. Osimertinib in untreated

EGFR-mutated advanced non–small-cell lung cancer. New

England journal of medicine. 2018;378(2):113-125.

Okuma Y, Kubota K, Shimokawa M, Hashimoto K,

Kawashima Y, Sakamoto T, et al. First-line osimertinib for

previously untreated patients with NSCLC and uncommon

EGFR mutations: the UNICORN phase 2 nonrandomized

clinical trial. JAMA oncology. 2024;10(1):43-51.